Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma
NCT02656706Phase 2Active, not recruiting
- Sponsor
- Brown University
- Start
- Jul 2016
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in melanoma, sponsored by Brown University. Primary endpoints: Number of Participants With Treatment Related Toxicities at 7 months, Progression-Free Survival at 5 years and 1 more. Started Jul 2016; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02656706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02656706.